In order to assess 18F-IRS specific binding to patients carrying mutations in EGFR on clinical, we will recruit patients with NSCLC harboring various EGFR mutation, such as L858R mutant EGFR, WT EGFR and L858R/T790M dualmutant EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.